These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


175 related items for PubMed ID: 2195845

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Aminohexane diphosphonate in the treatment of Paget's disease of bone.
    Atkins RM, Yates AJ, Gray RE, Urwin GH, Hamdy NA, Beneton MN, Rosini S, Kanis JA.
    J Bone Miner Res; 1987 Aug; 2(4):273-9. PubMed ID: 3455614
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Long-term biochemical response after bisphosphonate therapy in Paget's disease of bone. Proposed intervals for monitoring treatment.
    Alvarez L, Peris P, Guañabens N, Vidal S, Quintó L, Monegal A, Pons F, Ballesta AM, Muñoz-Gómez J.
    Rheumatology (Oxford); 2004 Jul; 43(7):869-74. PubMed ID: 15054158
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Rapid, divergent changes in spinal and forearm bone density following short-term intravenous treatment of Paget's disease with pamidronate disodium.
    Price RI, Gutteridge DH, Stuckey BG, Kent GN, Retallack RW, Prince RL, Bhagat CI, Johnston CA, Nicholson GC, Stewart GO.
    J Bone Miner Res; 1993 Feb; 8(2):209-17. PubMed ID: 8442439
    [Abstract] [Full Text] [Related]

  • 11. Measurement of urinary excretion of nonisomerized and beta-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's disease.
    Garnero P, Gineyts E, Schaffer AV, Seaman J, Delmas PD.
    Arthritis Rheum; 1998 Feb; 41(2):354-60. PubMed ID: 9485094
    [Abstract] [Full Text] [Related]

  • 12. Long-term elevation of 1,25-dihydroxyvitamin D after short-term intravenous administration of pamidronate (aminohydroxypropylidene bisphosphonate, APD) in Paget's disease of bone.
    Devlin RD, Retallack RW, Fenton AJ, Grill V, Gutteridge DH, Kent GN, Prince RL, Worth GK.
    J Bone Miner Res; 1994 Jan; 9(1):81-5. PubMed ID: 8154313
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Prediction of the outcome of treatment of Paget's disease of bone with bisphosphonates from short-term changes in the rate of bone resorption.
    Papapoulos SE, Frölich M.
    J Clin Endocrinol Metab; 1996 Nov; 81(11):3993-7. PubMed ID: 8923849
    [Abstract] [Full Text] [Related]

  • 16. Paget's disease of bone treated in five days with AHPrBP (APD) per Os.
    Thiébaud D, Jaeger P, Burckhardt P.
    J Bone Miner Res; 1987 Feb; 2(1):45-52. PubMed ID: 3455156
    [Abstract] [Full Text] [Related]

  • 17. [The treatment of Paget's disease of bone with second-generation bisphosphonates via intravenous infusion].
    Arboleya L, Sánchez J, Iglesias G, Arranz JL.
    Rev Clin Esp; 1993 Dec; 193(9):467-71. PubMed ID: 8108576
    [Abstract] [Full Text] [Related]

  • 18. Treatment of Paget's disease of bone with intravenous 4-amino-1-hydroxybutylidene-1,1-bisphosphonate.
    Adami S, Salvagno G, Guarrera G, Montesanti F, Garavelli S, Rosini S, Lo Cascio V.
    Calcif Tissue Int; 1986 Oct; 39(4):226-9. PubMed ID: 2947663
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Sustained biochemical effects of short treatment of Paget's disease of bone with dichloromethylene diphosphonate.
    Chapuy MC, Charhon SA, Meunier PJ.
    Metab Bone Dis Relat Res; 1983 Oct; 4(6):325-8. PubMed ID: 6229683
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 9.